Faculty Bibliography

Treatment of HIV infection before it causes symptoms may delay progression to AIDS but does not prolong survival, a new study has found. The study, reported Saturday in the British Medical Journal, supports findings from the Concorde study in Europe that in 1993 called into question a standard practice of prescribing the drug AZT for people infected with HIV, or human immunodeficiency virus, which causes AIDS. The British study involved 436 AIDS patients at St. Mary's Hospital Medical School in London. Its authors said they hoped it would raise more discussion about the relative merits of treating HIV early or after symptoms develop and stimulate scientists to focus more studies on the quality of life among those treated for HIV infection

An advisory panel to the Food and Drug Administration unanimously recommended Friday that one AIDS patient be allowed to receive an experimental bone marrow transplant from a baboon. Baboons are naturally resistant to HIV-1, the virus that is causing the overwhelming majority of AIDS cases in the world. The underlying aim of the experiment is to determine whether uninfected baboon cells will join the HIV-infected human marrow to restore the body's immune function. 'We're ready to go,' the advisory committee was told by Dr. Steven Deeks, an investigator at UC San Francisco, where the experiment will be carried out. The timing of the experiment will depend in part on when the investigators provide the FDA with additional data and when local ethics and bio-safety committees in San Francisco give final approval

An advisory panel to the Food and Drug Administration unanimously recommended Friday that one AIDS patient be allowed to receive an experimental bone marrow transplant from a baboon. Baboons are naturally resistant to HIV-1, the virus that is causing the overwhelming majority of AIDS cases in the world. The underlying aim of the experiment is to determine whether uninfected baboon cells will join the HIV-infected human marrow to restore the body's immune function. After the vote, two FDA officials said they expected the agency to approve the experiment after the researchers from the University of Pittsburgh and the University of California at San Francisco provide additional data

According to a report issued on Jul 13, 1995 by the Institute of Medicine of the National Academy of Sciences, new steps are needed to prevent the disastrous spread of another dangerous infectious agent like HIV in the nation's blood supply. The report said the ability of the US's blood banking and public systems to identify and guard against unknown microbes is weak

The Food and Drug Administration has approved the marketing of the first prescription drug for the treatment of impotence, a condition that affects 10 million to 20 million American men. The FDA's action Thursday gives Upjohn Co. in Kalamazoo, Mich., permission to market the drug, alprostadil, under the brand name Caverject. Upjohn already markets alprostadil, a naturally occurring form of prostaglandin E11, for pediatric cardiac use. Caverject is a synthetic version of alprostadil. The FDA approved use of Caverject for a broad group of patients whose impotence is due to psychological factors like sexual performance anxiety, nerve dysfunction or damage to arteries, capillaries and veins. Use was also approved to help diagnose erectile dysfunction, which is the consistent inability to achieve and maintain a penile erection

The FDA on Jul 6, 1995 approved the marketing of alprostadil, the first prescription drug for the treatment of impotence, a condition that affects 10 million to 20 million American men

The FDA on Jul 6, 1995 approved the marketing of the first prescription drug for the treatment of impotence, a condition that affects 10 million to 20 million American men. The action gave the maker, the Upjohn Co, permission to market the drug, alprostadil, under the brand name Caverject